Salivary Science in the Lab: A Comprehensive Review of Analytical Platforms and Possibilities

Source: IntechOpen, by Bruno Špiljak; Bojan Poposki; Zrinka Ivanišević; Stjepanka Lešić; Ivana Šutej (October 9, 2026). AI-generated summary by biochip.com, published October 13, 2026. Not independently reviewed.

A review by Bruno Špiljak and colleagues examines how laboratories can turn saliva into reliable diagnostic information, from established immunoassays and molecular tests to emerging microfluidic systems, biosensors, and wearable devices. The central message is practical: saliva is easy to collect, but it is not a simpler version of blood. Its usefulness depends on matching the collection method and analytical platform to a specific biological target and clinical purpose. That distinction matters as developers pursue decentralized, repeatable testing that patients can perform without a blood draw.

Saliva Is a Rich but Variable Sample

Saliva contains electrolytes, enzymes, proteins, nucleic acids, metabolites, extracellular vesicles, cells, and microorganisms. It combines material made in salivary glands with components from blood, gum fluid, oral tissues, food residues, and the mouth's microbial community. That mix can be useful because it captures local oral disease and, in some cases, systemic biology.

But the same complexity creates measurement problems. Viscosity, mucins, microbes, particles, proteases, and low concentrations of a target molecule can interfere with a test. Salivary flow also changes with hydration, stimulation, time of day, medication, and gland function, which means a measured concentration may shift even when the body’s total output of an analyte does not.

Platforms Must Fit the Question

The review covers biochemical and enzyme assays, immunoassays, nucleic acid amplification, proteomics, metabolomics, microbial culture, and sequencing-based microbiome analysis. Each platform addresses a different type of signal. An immunoassay, for example, uses binding molecules to recognize a protein, much like a lock recognizing a particular key, while nucleic acid amplification copies genetic material until it becomes detectable.

Newer approaches combine sample handling and detection in compact formats. Microfluidic systems move tiny volumes of fluid through small channels, which can automate steps such as mixing, filtering, and reaction setup. Biosensors convert a biological interaction into a readable signal, while CRISPR-based diagnostics use programmable genetic recognition to identify target nucleic acid sequences.

These tools could support point-of-care testing, but the review stresses that an appealing device format does not guarantee clinical performance. Developers need saliva-specific calibration, quality control, reference-method comparisons, predefined clinical thresholds, and external validation in new patient groups.

Where Evidence Is Strongest

Saliva-based nucleic acid amplification testing for SARS-CoV-2 provides one of the clearest examples of an assay-specific workflow. A meta-analysis of 23 studies with 11,582 paired specimens estimated 87% pooled sensitivity and 99% specificity relative to nasopharyngeal sampling. Performance varied by collection method, assay, clinical setting, and disease stage, with the strongest sensitivity in symptomatic outpatients.

For periodontal disease, salivary biomarker combinations have shown pooled sensitivity and specificity ranges of roughly 71% to 86% and 76% to 84%. Yet an active matrix metalloproteinase-8 point-of-care test had pooled sensitivity of 0.63 and specificity of 0.84, supporting its use as an adjunct rather than a replacement for a periodontal examination.

Why This Matters

Saliva could make repeated testing easier for children, older adults, people with difficult venous access, and participants in remote studies. It is especially useful when researchers need to follow changing signals such as hormones, drugs, or infectious agents over time. Self-collection can also expand participation beyond specialist clinics.

Still, home collection transfers important laboratory steps to the participant. In one salivary cortisol study, self-reported adherence reached 96.4%, while electronically verified timing compliance was 81%. Clear instructions about timing, food and drink, oral hygiene, medication use, collection duration, transport, and storage are therefore part of the test itself.

The next stage for salivary sensing platforms is not simply finding more candidate biomarkers. It is proving that particular device and assay combinations work consistently in the people and settings where they are meant to be used. With that validation, saliva can complement conventional specimens in screening, diagnosis, treatment monitoring, and decentralized research.

Topics: Diagnostics & precision medicine

Start here: What is a biochip?